Gano Kyle, Chief Business Development Officer at Neurocrine Biosciences (NBIX), has filed 44 Form 4 transactions, all in the company’s stock. The pattern is heavily skewed toward the sell side: open-market sales total roughly $25.3 million, with no open-market purchases on record. The most recent cluster, dated February 13, 2026, consists entirely of compensation-related grants (code "A") and automatic tax-withholding dispositions (code "F") totaling about $989,609, alongside option exercises (code "M") valued at zero. These are mechanical events, not discretionary trades.
The discretionary selling is concentrated in a handful of open-market sales (code "S"). The largest was on January 16, 2026, when Kyle sold shares worth approximately $4.59 million, paired with an option exercise valued at $1.24 million. A second sale that same day brought in another $240,478. Earlier sales include $425,911 on November 4, 2025, and a pair of February 2025 sales totaling roughly $298,908. Across the trailing twelve months, the sell bias is unambiguous: six recent open-market sales versus zero purchases, with total proceeds exceeding $25 million. The absence of any buy-side activity suggests Kyle has been a consistent net seller, though the data alone does not indicate whether this reflects portfolio diversification, tax planning, or other personal considerations.
AI-assisted summary